Review of clinical research on antiplatelet therapy in percutaneous coronary intervention in 2023 / 中国介入心脏病学杂志
Chinese Journal of Interventional Cardiology
; (4): 5-8, 2024.
Article
de Zh
| WPRIM
| ID: wpr-1024404
Bibliothèque responsable:
WPRO
ABSTRACT
@#How to optimize antiplatelet therapy in percutaneous coronary intervention is always a daily problem in clinical practice.In 2023,the research mainly focused on evaluating the efficacy and safety of single-drug therapy strategy of P2Y12 receptor antagonist without aspirin and de-escalation of antiplatelet therapy,which provided more evidence-based evidence for clinical these strategies.The future direction will include applicatian of new therapeutic targets,developing new antiplatelet drugs,using existing drugs to implement more innovative antithrombotic therapy schemes and further research to verify the more widely used contemporary antiplatelet strategies.
Texte intégral:
1
Indice:
WPRIM
langue:
Zh
Texte intégral:
Chinese Journal of Interventional Cardiology
Année:
2024
Type:
Article